Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Short-term Investments (2022 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Short-term Investments for 4 consecutive years, with $203.7 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 22.62% to $203.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $203.7 million through Dec 2025, down 22.62% year-over-year, with the annual reading at $203.7 million for FY2025, 22.62% down from the prior year.
  • Short-term Investments hit $203.7 million in Q4 2025 for ARS Pharmaceuticals, down from $228.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $263.2 million in Q4 2024 to a low of $19.9 million in Q1 2022.
  • Historically, Short-term Investments has averaged $154.4 million across 4 years, with a median of $172.2 million in 2023.
  • Biggest five-year swings in Short-term Investments: skyrocketed 789.75% in 2023 and later decreased 22.62% in 2025.
  • Year by year, Short-term Investments stood at $63.9 million in 2022, then surged by 146.45% to $157.4 million in 2023, then soared by 67.23% to $263.2 million in 2024, then dropped by 22.62% to $203.7 million in 2025.
  • Business Quant data shows Short-term Investments for SPRY at $203.7 million in Q4 2025, $228.7 million in Q3 2025, and $188.6 million in Q2 2025.